CD40L-Enhanced TIL therapy for advanced melanoma
Treatments studied
Part of Cancer, Eyes & vision, Skin clinical trials.
This trial tests a new way to treat advanced melanoma by taking immune cells from your tumor, enhancing them in the lab to fight better, and giving them back to you. It is for people whose melanoma has spread or cannot be removed, and who have already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced melanoma (stage 3 or 4) that cannot be surgically removed or has spread, including melanoma of the skin, eye, or mucous membranes.
- You must have already tried at least one standard treatment (like immunotherapy or targeted therapy) and it stopped working, you couldn't tolerate it, or your doctor says it's not right for you.
- You must be 18 years or older, and if over 65, may need a heart check-up.
- You must have a tumor that can be surgically removed to collect cells for the treatment, and another tumor to measure how the treatment works.
- You must not have serious heart, lung, or immune system conditions, or be pregnant or breastfeeding.
- You must be willing to use birth control during the study and for up to 1 year after treatment (for women) or 6 months (for men).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a personalized cell therapy using your own immune cells (TILs) grown in a lab. It is for people with advanced melanoma that did not respond to or stopped responding to prior immunotherapy.
This trial tests using your own immune cells (TILs) to fight advanced uveal melanoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, or angiosarcoma. It aims to see if this treatment can shrink tumors or slow their growth.
This trial tests a new way to boost your immune cells after they are collected from your tumor and grown in a lab. Instead of high-dose IL-2, you would get a modified version called ANV419, which may have fewer side effects.
This trial tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to other therapies. It involves taking immune cells from a tumor, growing them in a lab, and giving them back to fight the cancer.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.